Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
|
25625240 |
2015 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 has been postulated to be a colon cancer stem cell (CSCs) marker.
|
19724847 |
2009 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD133 is one of the most important cancer-initiating (stem) cell markers and was confirmed to be expressed in solid cancers such as colon cancer.
|
20379837 |
2010 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling.
|
21601882 |
2012 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.
|
22871210 |
2012 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133-positive cancer stem cells in colon cancer are resistant to conventional chemotherapy.
|
23245395 |
2013 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD133 expression was evaluated by flow cytometry in three colon cancer cell lines (HCT116, Lovo and DLD1).
|
27387378 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD133 and CD44 were regarded as markers of CCSCs and they were found to be co-expressed in the HCT116 colon cancer cell line.
|
27600678 |
2016 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133-containing MVs induced the development of chemoresistance by abolishing the inhibitory effects of anti-epidermal growth factor receptor (EGFR) drugs on cell proliferation and motility in colon cancer.
|
30521383 |
2019 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 was considered colon cancer stem cell marker and used to sort CD133+ and CD133- cells by magnetic cell sorting.
|
31390540 |
2019 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133+ colon cancer cells (LoVo) were infected with the lentiviral vector carrying CD133 gRNA and purified cell by culturing single cell colonies.
|
31393941 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
According to the cancer stem cell (CSC) model, higher CD133 expression in tumor tissue is associated with metastasis and poor prognosis in colon cancer.
|
23577199 |
2013 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although the <i>TP53</i> gene is frequently mutated in colon cancer, it remains not fully understood whether and how tumor protein p53 (p53) is associated with CD133 expression in colon cancer cells.
|
29928431 |
2018 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Assessment of neutralizing interleukin-4 effect on CD133 gene expression in colon cancer cell line.
|
28578295 |
2017 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Automated FISH analysis was performed on 13 different colon cancer samples that had been stained for CD133; each sample was scored for MYC, ZNF217 and Chromosome 6 in CD133 positive and negative glands.
|
20966547 |
2010 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Automated FISH analysis was performed on 13 different colon cancer samples that had been stained for CD133; each sample was scored for MYC, ZNF217 and Chromosome 6 in CD133 positive and negative glands.
|
21656271 |
2011 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Care must be taken if CD133 is used as the only marker of cancer stem cells in colon cancer, especially in established cell lines.
|
20023382 |
2010 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD66c was absent in CD133-positive cells that were isolated from normal colon, whereas its expression was brightest (CD66c(bright) ) in CD133-positive cells from colon cancer samples.
|
23027178 |
2013 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Different results were also obtained using the two antibodies to analyze the expression of the CD133 molecule in human colon cancers.
|
20333645 |
2010 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery.
|
20332776 |
2010 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Flow cytometry revealed that CD133 was bimodally expressed in SW620 cells among eight colon cancer cell lines.
|
22954703 |
2012 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we discuss the potential use of the CD133 antigen in concert with Musashi-1 as markers to identify the colon cancer stem cell population.
|
18235245 |
2008 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, sorted CD133+ colon cancer cells exhibit no increased resistance to 5-FU, and CD133 levels exhibit no correlation with colon cancer patient survival or cancer recurrence.
|
27659530 |
2016 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study illustrates a novel target to eliminate the tumorigenic CD133(+) cell population in colon cancer and provides another rationale for the development of specific ATR-inhibitors.
|
21308861 |
2011 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, p-STAT3 may participate in the progression of the early stage of colon cancer through the up-regulation of CD133, which in turn induces survivin expression.
|
29432737 |
2018 |